WO1980000215A1 - Medicament against glaucoma - Google Patents
Medicament against glaucoma Download PDFInfo
- Publication number
- WO1980000215A1 WO1980000215A1 PCT/JP1979/000185 JP7900185W WO8000215A1 WO 1980000215 A1 WO1980000215 A1 WO 1980000215A1 JP 7900185 W JP7900185 W JP 7900185W WO 8000215 A1 WO8000215 A1 WO 8000215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glaucoma
- therapeutic agent
- acid
- present
- eye
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940012356 eye drops Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003885 eye ointment Substances 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 229940069265 ophthalmic ointment Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- SLMHDVBWFGHGSP-UHFFFAOYSA-K calcium;potassium;phosphate Chemical compound [K+].[Ca+2].[O-]P([O-])([O-])=O SLMHDVBWFGHGSP-UHFFFAOYSA-K 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940096825 phenylmercury Drugs 0.000 description 1
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical compound [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
Definitions
- the present invention relates to a therapeutic agent for glaucoma.
- Glaucoma is a group of diseases that cause functional and / or organic damage to the eye, based on sustained or repeated increases in intraocular pressure. There is an urgent need to lower intraocular pressure to normal levels in order to preserve it (Mitsuyoshi Kuni, Kazuo Iwata, Glaucoma, Kanbara Publishing Co., Ltd., 1968).
- the glaucoma treatment of the present invention is a one-pronged
- CI is [carbon bond between 3- and 4-position of the formula in and R is a lower respectively ⁇ ) Les ⁇ I and a group (or force I by port scan Chile I and backbone single bond or a double Indicates binding.]
- one of the lower ⁇ groups represented by ⁇ 1 and 2 is a linear or branched C 1 -C 4 group: a PI group
- a PI group For example, a meth I group, an ech 1 group, a ⁇ I ⁇ group, an iso ⁇ ⁇ ⁇ group, a " ⁇ group, a“ ” ⁇ group, etc. are included.
- Derivative acid addition salts include the usual pharmaceutically acceptable acid addition salts of such derivatives, for example, hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, fi acid,? Laic acid — Salts such as I-leic acid, citric acid and tartaric acid are included.
- the active ingredient compound represented by the above general formula [I] is produced, for example, as described in Japanese Patent Publication No. 53-10994, and has a bronchodilator effect to treat bronchial asthma. It is a compound known as an agent.
- the present invention relates to a series of known I-repostry IU derivatives as therapeutic agents for bronchial asthma, irrespective of the efficacy of the therapeutic agents.]? It has been found that there is a compound capable of exhibiting the effect of reducing intraocular pressure as a drug for treating glaucoma.
- the therapeutic agent for glaucoma of the present invention is obtained by mixing a derivative represented by the single branch type [I] or an acid addition salt thereof with a conventional carrier for ophthalmic preparations. Is prepared.
- a conventional carrier for ophthalmic preparations Is prepared.
- the dosage unit form any of various usual forms can be adopted arbitrarily, for example, ophthalmic ointments and eye drops for topical administration, and tablets, granules, injections and the like for systemic administration. an exemplary Te; ⁇ You can.
- the therapeutic agent of the present invention is preferably in the form of eye drops.
- the dose of the therapeutic agent of the present invention is not particularly limited. Usually, the amount of the active ingredient in the therapeutic agent is one adult per day]? 0.01 to 0.5, preferably 0.05 to 0.1. As a rule, administration is preferably divided into two or three times a day. The amount of the active ingredient in the therapeutic agent is usually in the range of about 0.04 to 2% by weight.
- the therapeutic agent of the present invention can be produced by a conventional method. Specifically, a derivative represented by the general formula [I] or an acid addition salt thereof is used as an active ingredient, which is mixed with a suitable base material and then shaped as necessary, thereby producing a product manufactured by J9. Is done.
- the therapeutic agent is an ophthalmic ointment, eye drop, injection or the like, it is manufactured by further sterilizing.
- the base depends on the form of the therapeutic agent.
- a conventional emulsion base, water-soluble base, suspending base and the like can be used.
- Representative examples of such bases include, for example, white cellulose, purified lanthanum, and liquid paraffin.
- the therapeutic agent of the present invention may further contain, for example, a solubilizing agent, a stabilizer, a buffer, an antioxidant, a preservative, and the like.
- a solubilizing agent include force J ft / t J O O O O O O O O O O O O O O O ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ N ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ D — te
- the preservatives include black tannin, sodium chloride, sodium chloride, titanium chloride, titanium chloride, phenylmercury, and mercury salt, chimerosa. Examples are I, phenomena) layer (I-co-Ile, meth) reparaben, and 0-by-1 reparabe.
- the eye drop is preferably made isotonic with tears, and therefore, an isotonic agent such as sodium chloride can be added as necessary. Further, the eye drops are desirably adjusted to a pH of 5.5 to 8.5, preferably 6.5 to 7.5.
- the therapeutic agent for glaucoma of the present invention is administered according to various administration methods according to the dosage unit form.
- the solution is dropped on the eye from an appropriate drip container or sprayed on the eye by a spraying device.
- a spraying device In the case of an eye ointment, it is applied to the eye.
- Tablets and granules are orally administered, and injections are administered subcutaneously, intramuscularly or intravenously, and in any case, the desired therapeutic effect can be similarly exerted.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8623178A JPS5513241A (en) | 1978-07-14 | 1978-07-14 | Remedy for glaucoma |
| JP78/86231 | 1978-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1980000215A1 true WO1980000215A1 (en) | 1980-02-21 |
Family
ID=13881010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1979/000185 WO1980000215A1 (en) | 1978-07-14 | 1979-07-13 | Medicament against glaucoma |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0020765A1 (en, 2012) |
| JP (1) | JPS5513241A (en, 2012) |
| CH (1) | CH643143A5 (en, 2012) |
| DE (1) | DE2952959C2 (en, 2012) |
| GB (1) | GB2039739B (en, 2012) |
| NL (1) | NL7920004A (en, 2012) |
| SE (1) | SE451070B (en, 2012) |
| WO (1) | WO1980000215A1 (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309432A (en) * | 1979-01-30 | 1982-01-05 | Otsuka Pharmaceutical Company, Ltd. | Compositions for treating glaucoma containing a carbostyril |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57172004A (en) * | 1981-04-17 | 1982-10-22 | Nichireki Chem Ind Co | Construction of bitminous thin layered pavement |
| FR2539413A1 (fr) * | 1983-01-17 | 1984-07-20 | Pos Lab | Carbostyriloximinopropanolamines utiles comme medicaments et procede pour leur preparation |
| JPH0726362B2 (ja) * | 1985-04-08 | 1995-03-22 | 日瀝化学工業株式会社 | 歴青質舗装体の施工方法 |
| AU3191795A (en) * | 1994-08-10 | 1996-03-07 | Otsuka Pharmaceutical Co., Ltd. | Method of preventing and treating ophthalmic inflammation and/or wound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5310994A (en) * | 1976-05-26 | 1978-01-31 | Sahlertz E H | Photoelectric indicator |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5310994B2 (en, 2012) * | 1974-06-13 | 1978-04-18 | ||
| US4026897A (en) * | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
-
1978
- 1978-07-14 JP JP8623178A patent/JPS5513241A/ja active Granted
-
1979
- 1979-07-13 NL NL7920004A patent/NL7920004A/nl unknown
- 1979-07-13 DE DE19792952959 patent/DE2952959C2/de not_active Expired
- 1979-07-13 CH CH205680A patent/CH643143A5/de not_active IP Right Cessation
- 1979-07-13 GB GB8007253A patent/GB2039739B/en not_active Expired
- 1979-07-13 WO PCT/JP1979/000185 patent/WO1980000215A1/ja unknown
-
1980
- 1980-02-25 EP EP79900778A patent/EP0020765A1/fr not_active Ceased
- 1980-03-13 SE SE8001981A patent/SE451070B/sv not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5310994A (en) * | 1976-05-26 | 1978-01-31 | Sahlertz E H | Photoelectric indicator |
Non-Patent Citations (2)
| Title |
|---|
| Osaka-fu Byoin Yakuzaishi-kai Henshu "Iyakuhin Yoran (Sogo Shinpan)" Third Edition (1976-8-20) Yakugyo Jihosha P.301 Ryokunaisho Chiryozai no Ko. * |
| See also references of EP0020765A4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309432A (en) * | 1979-01-30 | 1982-01-05 | Otsuka Pharmaceutical Company, Ltd. | Compositions for treating glaucoma containing a carbostyril |
Also Published As
| Publication number | Publication date |
|---|---|
| SE8001981L (sv) | 1980-03-13 |
| JPS611007B2 (en, 2012) | 1986-01-13 |
| GB2039739A (en) | 1980-08-20 |
| SE451070B (sv) | 1987-08-31 |
| EP0020765A1 (fr) | 1981-01-07 |
| EP0020765A4 (fr) | 1980-12-02 |
| NL7920004A (nl) | 1980-05-30 |
| JPS5513241A (en) | 1980-01-30 |
| GB2039739B (en) | 1983-01-26 |
| DE2952959T1 (en, 2012) | 1981-01-08 |
| CH643143A5 (de) | 1984-05-30 |
| DE2952959C2 (de) | 1986-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5201795B2 (ja) | 掻痒抑制剤 | |
| RU2494727C2 (ru) | Фармацевтическая композиция, содержащая фторхинолоновое антибиотическое лекарственное средство | |
| JPH05507916A (ja) | 眼科用アミノステロイド | |
| RU2370265C1 (ru) | Гель, обладающий противовоспалительным и противоаллергическим действием | |
| WO2013065720A1 (ja) | 眼科用水性組成物 | |
| KR101322527B1 (ko) | 잔탄 검 및 테르페노이드를 포함하는 점안제 | |
| EP1889620A1 (en) | Eye drop containing roflumilast | |
| JP2021532145A (ja) | 眼を治療するための組成物及び方法 | |
| JP2011093923A (ja) | 点眼剤 | |
| JP2021091697A (ja) | 水性点眼点鼻用組成物 | |
| JP2024111298A (ja) | 水性組成物その陸 | |
| JPWO2006049250A1 (ja) | 眼内移行性促進水性点眼剤 | |
| US5276044A (en) | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions | |
| JPH0637388B2 (ja) | 水性液剤 | |
| WO1980000215A1 (en) | Medicament against glaucoma | |
| EP0069075B1 (en) | Pharmaceutical preparation for treating glaucoma and ocular hypertension | |
| JP4801300B2 (ja) | 外用液状組成物 | |
| JP6253756B2 (ja) | 眼科用水性組成物 | |
| KR20220068131A (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
| US4322425A (en) | Compositions for treating glaucoma | |
| JP4470393B2 (ja) | 安定である点眼剤 | |
| JP2536786B2 (ja) | 安定な点眼剤 | |
| JPS5833202B2 (ja) | ガンカヨウシヨホウノ アンテイカホウ | |
| JPH06227988A (ja) | 眼科用外用剤 | |
| JPS5951928B2 (ja) | 緑内障治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Designated state(s): CH DE GB NL SE US |
|
| AL | Designated countries for regional patents |
Designated state(s): FR |
|
| RET | De translation (de og part 6b) |
Ref country code: DE Ref document number: 2952959 Date of ref document: 19810108 Format of ref document f/p: P |